COMPANY

Teva

Also known as Teva Pharmaceuticals

Profile checked Oct 10, 2026

Connect

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-12

Deal Deal · $57.5M · announced Aug 28, 2026 Company release ↗
Source quote
- Aug 28, 2026 · Company release ↗
  “Under the terms of the Agreement, Teva would acquire worldwide rights to the assets including dexmedetomidine sublingual film for an upfront payment of $57.5 million and up to an additional $67.5 million in contingent payments.”
Deal Deal · amount not disclosed · announced Jul 9, 2026 Company release ↗
Source quote
- Jul 9, 2026 · Company release ↗
  “Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis”
Deal Deal · $700M · announced Apr 29, 2026 Company release ↗
Source quote
- Apr 29, 2026 · Company release ↗
  “Upon closing, Teva will pay $700 million, and Emalex’s shareholders will be eligible to receive up to $200 million based on future commercial milestones as well as royalties on global net sales of ecopipam, subject to regulatory approval.”

From the company’s own releases; this list is partial. All raises and deals